ImmuDyne, a health and wellness lifestyle company with a portfolio of patented products with applications in the wellness lifestyle, skin care, anti-aging, fitness and health markets, today unveiled its plans to launch a new, proprietary dietary supplement in the U.S. alcohol consumption and hangover markets.
The company notes that approximately 1 in 6 adults binge drink, consuming an average of four to eight alcoholic beverage four or more times a month, according to a 2010 report published by the Centers for Disease Control and Prevention (CDC). In January of 2013, the CDC released the findings of another study demonstrating that excessive alcohol consumption cost U.S. taxpayers $223.5 billion in 2006 – roughly 72 percent of these costs resulted from lost or decreased work productivity due.
“The CDC statistics show that the majority of American adults drink and many drink excessively. Regardless of how much alcohol they consumed the night before, most Americans need to fulfill their daily professional and personal obligations the next morning,” Karen Kingston, chief marketing officer of IMMD stated in the press release. “Based on the scientific evidence and market feedback that we have gathered so far, we believe our new proprietary, peri-/post- alcohol consumption (PAC) product will help improve the daily cognitive and physical functioning of people who enjoy drinking alcohol by priming their immune system.”
Mark McLaughlin, president and CEO, said the company plans on featuring an event to demonstrate the new product, which the IMMD anticipates launching later this year.
“The launch of our proprietary PAC product will fill a large void – one of several market opportunities where we see potential in significantly monetizing our assets,” McLaughlin stated in the press release. “As we position the company for these opportunities, ImmuDyne is preparing for an exclusive event that will showcase our PAC product and provide us with valuable market feedback. Details of the event will be announced mid-June.”
For more information visit www.immudyne.com
Let us hear your thoughts below: